From the June 2022 issue of HealthCare Business News magazine
US to stop shipping highly enriched uranium (HEU) overseas for Mo-99
The United States announced in February it would be halting shipments of highly enriched uranium overseas to produce molybdenum-99 for its medical imaging needs.
Secretaries Jennifer Granholm and Xavier Becerra for the Department of Energy and the Health and Human Services, respectively, announced in December that the U.S. is now able to meet sufficient Mo-99 demand with its domestic source and no longer will need to ship HEU to facilities abroad, according to Physics Today. This follows the last in a series of grants issued as part of a nine-year campaign for growing the country’s domestic source, which it lacked for almost 30 years.
Ad Statistics
Times Displayed: 19681
Times Visited: 367 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
“The secretaries’ bold action puts one dangerous nuclear genie back in the bottle and brings to fruition more than three decades of efforts,” Alan Kuperman, coordinator of the Nuclear Proliferation Prevention Project at the University of Texas at Austin, told Physics Today.
From 1989 to 2018, the U.S. had no place to produce Mo-99, the parent isotope of technetium 99m, which is used as an agent in 40,000 PET and other nuclear medical imaging procedures daily across the country. As a result, it relied heavily on foreign imports from reactors in Canada and Europe, to which it would supply HEU for production.
Congress enacted a funding program in the American Medical Isotopes Production Act of 2012. Under this program, the NNSA awarded grants to aspiring U.S. producers of Mo-99, with the recipients required to match funding. One recipient, NorthStar, began producing Mo-99 in the U.S. in 2018, making it the first and only U.S.-based source in over 25 years. As part of the grant program, the company agreed to meet certain production capacities by the end of 2023. It expects to be able to produce 3000 six-day curies weekly (1500 by each of its two manufacturing processes) and says it already has the capacity to meet 20% of U.S. demand for the isotope.
